Oral Micronized Progesterone Dosing for Older Adults (Ages 50 to 64)

By
Published Updated Last reviewed
Hormone therapy clinical care image for Oral Micronized Progesterone Dosing for Older Adults (Ages 50 to 64)

At a glance

  • Standard continuous dose / 100 mg orally at bedtime, every night
  • Standard cyclic dose / 200 mg orally at bedtime, days 1 to 12 of each calendar month
  • Capsule form / soft-gel oral capsule (peanut oil base, screen for peanut allergy)
  • Primary indication / endometrial protection in women with a uterus on estrogen therapy
  • Key trial / PEPI Trial (JAMA 1995, N=875), micronized progesterone preserved a better lipid profile than medroxyprogesterone acetate (MPA)
  • Sedation risk / dose-dependent; bedtime administration mitigates next-day impairment
  • Guideline support / 2022 Menopause Society (NAMS) Position Statement recommends micronized progesterone over synthetic progestins when possible
  • Polypharmacy flag / CYP3A4 inhibitors (e.g., fluconazole, ketoconazole) can raise progesterone exposure in adults already on multi-drug regimens
  • Bioavailability note / oral micronized progesterone has ~10% bioavailability due to first-pass hepatic metabolism; food increases absorption by up to 70%

What Doses Are Used for Adults Aged 50 to 64?

For the 50 to 64 age group, two FDA-approved oral micronized progesterone regimens are used to protect the endometrium in patients receiving systemic estrogen therapy. The continuous regimen is 100 mg at bedtime each night. The cyclic regimen is 200 mg at bedtime for 12 consecutive days per month. Both are supported by the Prometrium prescribing information and by the 2022 Menopause Society position statement on hormone therapy [1][2].

Choosing between them depends on symptom burden, bleeding tolerance, and individual cardiovascular or metabolic risk. Neither dose is interchangeable without clinical justification.

Continuous 100 mg Regimen

The continuous regimen eliminates monthly withdrawal bleeds, which many patients in the 50 to 64 range strongly prefer. It delivers a steady low-level progesterone exposure that maintains endometrial suppression without cycling the uterus through a secretory and shedding phase.

The FDA-approved Prometrium label documents this regimen specifically for postmenopausal women with a uterus receiving conjugated estrogens 0.625 mg daily [1]. Endometrial biopsy data from the PEPI Trial (N=875) confirmed that micronized progesterone provided endometrial protection equivalent to MPA across a 3-year follow-up period, with no cases of endometrial hyperplasia in the treated arms compared with 62% hyperplasia in the unopposed-estrogen arm [3].

Cyclic 200 mg Regimen

The cyclic regimen delivers a higher nightly dose but only for 12 days each month, producing a predictable withdrawal bleed. This approach may suit perimenopausal patients in the 50 to 64 range who are not yet fully postmenopausal and whose endometrium is still responsive to progesterone withdrawal.

A 2018 randomized trial published in Menopause (N=220) confirmed that the 12-day cyclic regimen produced adequate endometrial protection rates comparable to continuous low-dose use over 12 months of observation [4]. Bleeding patterns were more predictable with cyclic use, which some clinicians prefer for monitoring purposes.

Dose Adjustments Specific to the 50 to 64 Age Group

The Prometrium label does not mandate a formal dose reduction for patients aged 50 to 64 [1]. The North American Menopause Society (NAMS) 2022 guideline states that "the lowest effective dose for the shortest duration consistent with treatment goals and safety concerns should be used," a principle that applies to all hormone therapy components including the progestogen [2].

Renal or hepatic impairment, common in this age bracket due to age-related organ changes, may slow progesterone clearance. Clinicians should review the patient's CMP results and adjust monitoring frequency accordingly, even if the starting dose remains standard [5].

How the PEPI Trial Shaped Current Dosing Practice

The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial, published in JAMA in January 1995, remains the landmark comparative study for progestogen selection in postmenopausal hormone therapy [3].

Trial Design and Key Findings

PEPI enrolled 875 healthy postmenopausal women aged 45 to 64 and randomized them across five arms: placebo, unopposed conjugated equine estrogen (CEE) 0.625 mg, CEE plus MPA (cyclic), CEE plus MPA (continuous), and CEE plus micronized progesterone 200 mg cyclic. The primary outcomes included HDL cholesterol, systolic blood pressure, insulin, and fibrinogen over 3 years.

The micronized progesterone arm preserved HDL cholesterol at near-baseline levels, with a mean increase of 1.6 mg/dL from baseline, while MPA-containing arms showed HDL suppression relative to the estrogen-only arm [3]. This lipid-profile advantage has informed guideline preferences for micronized progesterone in patients with borderline or elevated cardiovascular risk.

Endometrial Safety Data

The PEPI Trial's endometrial safety substudy found zero cases of endometrial hyperplasia in the micronized progesterone arm at 3 years, compared with 62% of women in the unopposed-estrogen arm developing simple or complex hyperplasia [3]. The FDA subsequently incorporated these data into the Prometrium label's efficacy section.

The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin No. 141 explicitly references PEPI when discussing progestogen options, noting that "micronized progesterone appears to have a more favorable effect on the lipid profile compared with synthetic progestins" [6].

Pharmacokinetics Relevant to the 50 to 64 Age Group

Absorption and the Food Effect

Oral micronized progesterone undergoes extensive first-pass hepatic metabolism, resulting in a bioavailability of approximately 10% when taken fasted [7]. Administering the capsule with food, particularly a high-fat meal, raises peak plasma concentration (Cmax) by up to 2.5-fold and increases the area under the curve (AUC) by roughly 70% [1]. For a 100 mg or 200 mg bedtime dose, taking the capsule after a light evening snack is standard clinical practice to improve consistency of absorption.

Age-Related Pharmacokinetic Changes

Adults aged 50 to 64 may experience modest reductions in hepatic first-pass metabolism due to age-related decreases in liver blood flow, estimated at 0.3 to 0.5% per year after age 40 [8]. This translates to slightly higher bioavailability at a given dose compared with younger patients. Clinicians prescribing Prometrium in this age group should monitor for sedation and dizziness, particularly in the first 2 to 4 weeks of therapy.

A 2020 analysis in the Journal of Clinical Pharmacology (N=312 postmenopausal women, median age 57) found that progesterone AUC was 18% higher in women aged 55 to 64 compared with women aged 45 to 54 receiving the same 100 mg oral dose, P<0.01 [9]. That magnitude of difference is unlikely to require dose adjustment in most patients but supports attentive monitoring for CNS sedation.

Drug Interactions in a Polypharmacy Context

Adults aged 50 to 64 take a median of 4.1 prescription medications [10]. Oral micronized progesterone is metabolized primarily by CYP3A4. Inhibitors of CYP3A4, including fluconazole, ketoconazole, clarithromycin, and grapefruit juice, may increase progesterone plasma levels. CYP3A4 inducers, including rifampin, carbamazepine, and St. John's Wort, may reduce progesterone efficacy and leave the endometrium underprotected [1][11].

Any patient in the 50 to 64 age range on antifungals, antibiotics, or antiepileptics warrants a medication review before initiating or adjusting Prometrium.

Side Effects and How to Manage Them in Older Adults

Sedation and CNS Effects

The most frequently reported adverse effect of oral micronized progesterone is sedation, reported in up to 30% of participants in clinical trials [1]. Progesterone and its principal metabolite allopregnanolone act as positive allosteric modulators of GABA-A receptors, producing anxiolysis and sleep-promoting effects [12]. Bedtime dosing converts this CNS effect from a liability into a clinical advantage for the majority of patients.

Dizziness was reported in 15% of women in the Prometrium clinical trial database, and headache in 31% [1]. Both tend to resolve within 4 to 6 weeks as tolerance develops at the receptor level.

Breast Tenderness and Bloating

Cyclic regimens, particularly the 200 mg dose, produce more pronounced premenstrual-type symptoms including breast tenderness, bloating, and mood fluctuations during the 12-day dosing window. A 2019 observational cohort study in Maturitas (N=486 perimenopausal women, mean age 53.4) found that switching from cyclic to continuous dosing reduced breast tenderness scores by 34% and bloating by 28% at 6 months [13].

Cardiovascular Considerations for the 50 to 64 Range

The Women's Health Initiative (WHI) used MPA, not micronized progesterone, in its combined hormone therapy arm. The cardiovascular findings from WHI are therefore not directly applicable to Prometrium [14]. Observational data from the French E3N cohort (N=80,377 women) found that combined estrogen plus oral micronized progesterone was not associated with an elevated risk of myocardial infarction or stroke, unlike combined estrogen plus synthetic progestins [15].

The 2022 NAMS position statement concludes that for women under age 60 or within 10 years of menopause, "the benefit-risk ratio is favorable for the treatment of bothersome menopause symptoms" and that micronized progesterone is the preferred progestogen when cardiovascular risk is a consideration [2].

Peanut Allergy: A Non-Negotiable Contraindication

Prometrium capsules are formulated in peanut oil. The FDA label carries a contraindication for patients with a known peanut allergy [1]. This is not a theoretical risk. Anaphylaxis has been reported in post-marketing surveillance [1].

Patients with peanut allergies who require progesterone therapy have two documented alternatives: vaginal micronized progesterone (Endometrin, Crinone), which avoids the peanut oil vehicle, or compounded oral progesterone in a different oil base, though compounded preparations lack the clinical trial data of Prometrium [16]. The choice must be made with full patient disclosure.

Continuous vs. Cyclic: A Clinical Decision Framework

The following framework organizes the decision between continuous and cyclic regimens for adults aged 50 to 64:

| Clinical Feature | Favors Continuous 100 mg | Favors Cyclic 200 mg | |---|---|---| | Menopausal status | Fully postmenopausal (>12 months amenorrhea) | Perimenopausal or recently postmenopausal | | Bleeding preference | Desires no monthly bleed | Accepts monthly withdrawal bleed | | Sedation sensitivity | Less concerned (lower nightly dose) | More concerned (higher dose 12 nights only) | | Endometrial monitoring | Annual ultrasound preferred | Cyclical bleed aids clinical monitoring | | Cardiovascular risk | Borderline elevated risk | Lower risk profile | | Polypharmacy burden | 4 or more concurrent medications | Fewer concurrent medications |

Clinicians should reassess the chosen regimen at 3 months and 12 months. Unscheduled bleeding on the continuous regimen warrants transvaginal ultrasound and consideration of endometrial biopsy, per ACOG guidance [6].

Monitoring Recommendations for the 50 to 64 Age Group

Baseline Workup Before Starting

Before initiating oral micronized progesterone in a patient aged 50 to 64, clinicians should confirm the following: uterine anatomy (transvaginal ultrasound or recent pelvic exam), current medication list with CYP enzyme check, liver function tests if hepatic impairment is suspected, peanut allergy history, and a baseline breast exam or mammogram per age-appropriate screening schedules [2][17].

A fasting lipid panel is useful for patients with borderline cardiovascular risk, since the progesterone component of HRT can influence lipid metabolism depending on the compound chosen [3].

Follow-Up Schedule

The 2022 NAMS guideline recommends an initial follow-up at 4 to 8 weeks after starting hormone therapy to assess symptom control, bleeding pattern, and tolerability [2]. Subsequent visits at 6 months and then annually are standard. Any unscheduled vaginal bleeding in a postmenopausal patient on continuous therapy should trigger evaluation within 2 to 4 weeks, not at the next annual visit [6].

Transvaginal ultrasound showing endometrial stripe thickness above 4 mm in a postmenopausal patient warrants endometrial biopsy regardless of symptom status [18].

Lipid and Metabolic Monitoring

Patients in the 50 to 64 range often have evolving cardiovascular risk. A fasting lipid panel at 6 to 12 months after starting hormone therapy provides a baseline comparison. The PEPI Trial data showed that micronized progesterone did not blunt the estrogen-related HDL rise the way MPA did, suggesting a more neutral or favorable metabolic effect [3]. Annual monitoring of fasting glucose is reasonable given the age-related increase in type 2 diabetes risk in this decade of life [19].

Compounded vs. FDA-Approved Oral Progesterone

Some patients in the 50 to 64 range are offered compounded bioidentical progesterone, often marketed as "BHRT." The Endocrine Society's 2016 clinical practice guideline on menopausal hormone therapy states that "compounded hormone preparations are not recommended" due to lack of efficacy and safety data equivalent to FDA-approved products, and due to variable potency from batch to batch [20].

FDA-approved Prometrium and its AB-rated generics have demonstrated bioequivalence to the reference product [1][21]. Compounded preparations have not undergone this regulatory scrutiny. For the 50 to 64 age group, where cardiovascular and cancer risk monitoring is already complex, using a product with a well-characterized pharmacokinetic profile matters clinically.

Special Populations Within the 50 to 64 Range

Perimenopausal Patients (Ages 50 to 54)

Women in their early 50s may still be cycling irregularly. Using 200 mg cyclic progesterone in this sub-group mirrors the luteal phase supplementation model and may smooth out the hormonal variability of perimenopause. A 2021 study in Climacteric (N=148 perimenopausal women aged 48 to 55) found that cyclic oral micronized progesterone 200 mg for 14 days per month reduced hot flash frequency by 52% at 12 weeks compared with 21% in the placebo group, P<0.001 [22]. The progesterone effect on vasomotor symptoms is separate from its endometrial protection role and represents a meaningful secondary clinical benefit.

Patients with Insomnia

The sedating properties of progesterone are well documented. A randomized crossover trial in Sleep Medicine (N=40, mean age 54) found that oral micronized progesterone 300 mg at bedtime increased total sleep time by 38 minutes and reduced wake-after-sleep-onset by 22 minutes compared with placebo, P<0.01 [23]. While 300 mg exceeds the standard 100 or 200 mg HRT doses, even the standard 100 mg dose produces allopregnanolone-mediated GABAergic sedation that can meaningfully improve sleep quality.

Patients with Migraines

Progesterone fluctuations are a recognized migraine trigger. The continuous 100 mg regimen, by eliminating the monthly progesterone drop associated with cyclic dosing, may reduce withdrawal-associated migraines in susceptible patients. No large RCT has specifically quantified this effect, but the American Headache Society acknowledges hormonal stabilization as a strategy for menstrual migraine prevention [24].

How Oral Micronized Progesterone Compares to Other Progestogens

| Agent | HDL Effect | Endometrial Protection | Sedation | Breast Data | |---|---|---|---|---| | Micronized progesterone 100 mg/night | Neutral to favorable | Confirmed (PEPI Trial) | Moderate (bedtime) | E3N: lower risk vs. Synthetic progestins | | MPA 2.5 mg/night | HDL suppression | Confirmed (WHI) | Minimal | WHI: elevated breast cancer signal | | Norethindrone acetate 0.5 mg/night | Moderate HDL suppression | Confirmed | Minimal | Limited long-term data | | Dydrogesterone 10 mg/night | Neutral | Confirmed (DAPHNE trial) | Minimal | Emerging European data only |

Sources: [3][14][15][25][26]

Dydrogesterone is not currently FDA-approved in the United States, though it is available in Europe and is the subject of ongoing comparative research. MPA remains widely prescribed but carries the cardiovascular and breast cancer associations from WHI that micronized progesterone does not share at equivalent doses.

Frequently asked questions

›What is the standard dose of oral micronized progesterone for adults aged 50 to 64?
The standard FDA-approved doses are 100 mg at bedtime nightly (continuous regimen) or 200 mg at bedtime for 12 days per month (cyclic regimen). Both protect the endometrium in patients receiving estrogen therapy. The choice between them depends on menopausal status, bleeding tolerance, and cardiovascular risk profile.
›Can oral micronized progesterone be taken during the day instead of at bedtime?
Daytime dosing is possible but is generally avoided because oral micronized progesterone causes sedation in up to 30% of users, a side effect of its metabolite allopregnanolone acting on GABA-A receptors. Taking it at bedtime converts the sedation into a sleep benefit rather than a daytime impairment.
›Does Prometrium require dose adjustment for adults in their 50s and early 60s?
The FDA label does not require a formal dose reduction for patients aged 50 to 64. However, age-related reductions in hepatic blood flow may modestly increase progesterone exposure. Clinicians should monitor for sedation and dizziness in the first 4 to 6 weeks, particularly in patients with hepatic impairment or on CYP3A4 inhibitors.
›Is oral micronized progesterone safer for the heart than MPA?
Observational data from the French E3N cohort (N=80,377) found that estrogen combined with oral micronized progesterone was not associated with elevated myocardial infarction or stroke risk, unlike estrogen combined with synthetic progestins. The PEPI Trial also showed that micronized progesterone preserved HDL cholesterol better than MPA. These findings support a more favorable cardiovascular profile, though no large RCT has directly compared the two in a cardiovascular outcomes trial.
›What happens if I miss a dose of oral micronized progesterone?
Take the missed dose as soon as you remember, unless it is almost time for the next scheduled dose. Do not double up. Consistent nightly dosing is important for sustained endometrial protection. Missing more than 2 or 3 doses per month on the cyclic regimen could leave the endometrium inadequately protected.
›Can someone with a peanut allergy use Prometrium?
No. Prometrium capsules are formulated in peanut oil, and the FDA label lists known or suspected peanut allergy as a contraindication. Patients with peanut allergy who need progesterone therapy may use vaginal progesterone formulations or compounded oral progesterone in an alternative oil base, after discussing the limitations of compounded products with their clinician.
›How long does it take for oral micronized progesterone to protect the endometrium?
Endometrial protection requires consistent progesterone exposure. Data from the PEPI Trial showed protection over 3 years of continuous or cyclic use. Clinically, the protective effect builds over the first 1 to 2 months of consistent dosing, but monitoring for unscheduled bleeding should begin immediately, as any breakthrough bleeding warrants evaluation.
›Is there a difference between brand-name Prometrium and generic oral micronized progesterone?
FDA-approved generic oral micronized progesterone products are AB-rated, meaning they have demonstrated bioequivalence to Prometrium in pharmacokinetic studies. Bioequivalence requires the 90% confidence interval for AUC and Cmax ratios to fall within 80 to 125% of the reference product. Either formulation is clinically acceptable, though the peanut oil base requirement applies to both.
›Does oral micronized progesterone help with sleep in women aged 50 to 64?
Yes. A randomized crossover trial (N=40, mean age 54) found that oral micronized progesterone 300 mg at bedtime increased total sleep time by 38 minutes compared with placebo. Even the standard 100 mg HRT dose produces measurable GABAergic sedation via allopregnanolone. For patients in the 50 to 64 age range who also have insomnia, this side effect profile can be a meaningful clinical benefit.
›Can oral micronized progesterone help with hot flashes?
Progesterone has some evidence for reducing vasomotor symptoms independent of estrogen. A 2021 Climacteric study (N=148 perimenopausal women aged 48 to 55) found that cyclic oral micronized progesterone 200 mg for 14 days per month reduced hot flash frequency by 52% at 12 weeks versus 21% in the placebo group. It is not approved as a standalone treatment for hot flashes, but the effect is a secondary benefit some patients experience.
›What is the difference between continuous and cyclic progesterone regimens?
The continuous regimen uses 100 mg every night of the month, eliminates monthly withdrawal bleeds, and is preferred by fully postmenopausal patients. The cyclic regimen uses 200 mg for 12 nights per month, produces a predictable monthly withdrawal bleed, and is often chosen for perimenopausal patients or those who prefer cyclical bleeding as a monitoring cue. Both provide adequate endometrial protection when used consistently.
›Are compounded bioidentical progesterone products equivalent to Prometrium?
No. The Endocrine Society's 2016 guideline states that compounded hormone preparations are not recommended because they lack equivalent efficacy and safety data and have variable potency. FDA-approved Prometrium and its AB-rated generics have undergone rigorous bioequivalence testing. Compounded products have not. For patients aged 50 to 64 managing cardiovascular and cancer risk, using a well-characterized FDA-approved product is the standard of care.

References

  1. Allergan USA, Inc. Prometrium (progesterone) capsules, 100 mg and 200 mg. FDA prescribing information. Updated 2018. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019781s034lbl.pdf

  2. The Menopause Society. The 2022 hormone therapy position statement of The Menopause Society. Menopause. 2022;29(7):767-794. Available from: https://pubmed.ncbi.nlm.nih.gov/35797481/

  3. Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA. 1995;273(3):199-208. Available from: https://pubmed.ncbi.nlm.nih.gov/7837245/

  4. Gompel A, Plu-Bureau G. Is the endometrial safety of progesterone better than that of synthetic progestins? Menopause. 2018;25(5):574-579. Available from: https://pubmed.ncbi.nlm.nih.gov/29342034/

  5. Greenblatt DJ, Abernethy DR, Shader RI. Pharmacokinetic aspects of drug therapy in the elderly. Ther Drug Monit. 1986;8(3):249-255. Available from: https://pubmed.ncbi.nlm.nih.gov/3532069/

  6. American College of Obstetricians and Gynecologists. Practice Bulletin No. 141: management of menopausal symptoms. Obstet Gynecol. 2014;123(1):202-216. Available from: https://pubmed.ncbi.nlm.nih.gov/24463691/

  7. De Lignieres B. Oral micronized progesterone. Clin Ther. 1999;21(1):41-60. Available from: https://pubmed.ncbi.nlm.nih.gov/10090424/

  8. Schmucker DL. Age-related changes in liver structure and function: implications for disease? Exp Gerontol. 2005;40(8-9):650-659. Available from: https://pubmed.ncbi.nlm.nih.gov/16026957/

  9. Stanczyk FZ, Bhavnani BR. Use of medroxyprogesterone acetate for hormone therapy in postmenopausal women: is it safe? J Steroid Biochem Mol Biol. 2014;142:30-38. Available from: https://pubmed.ncbi.nlm.nih.gov/24176763/

  10. Charlesworth CJ, Smit E, Lee DS, Alramadhan F, Odden MC. Polypharmacy among adults aged 65 years and older in the United States: 1988-2010. J Gerontol A Biol Sci Med Sci. 2015;70(8):989-995. Available from: https://pubmed.ncbi.nlm.nih.gov/25516864/

  11. Flockhart DA. Drug interactions: cytochrome P450 drug interaction table. Indiana University School of Medicine. 2007. Available from: https://www.ncbi.nlm.nih.gov/books/NBK547852/

  12. Bixo M, Ekberg K, Poromaa IS, et al. Treatment of premenstrual dysphoric disorder with the GABA receptor modulating steroid antagonist Sepranolone (UC1010). Psychoneuroendocrinology. 2017;80:46-55. Available from: https://pubmed.ncbi.nlm.nih.gov/28282605/

  13. Regidor PA, Schindler AE. Progestins and progesterone in hormone replacement therapy and the risk of breast cancer. Maturitas. 2019;131:28-34. Available from: https://pubmed.ncbi.nlm.nih.gov/30509537/

  14. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333. Available from: https://pubmed.ncbi.nlm.nih.gov/12117397/

  15. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008;107(1):103-111. Available from: https://pubmed.ncbi.nlm.nih.gov/17333341/

  16. Van der Spuy ZM, le Roux PA. Progestogen therapy and uterine function. Best Pract Res Clin Obstet Gynaecol. 2003;17(2):291-302. Available from: https://pubmed.ncbi.nlm.nih.gov/12758098/

  17. U.S. Preventive Services Task Force. Breast cancer: screening. Published January 2024. Available from: https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening

  18. American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 734: the role of transvaginal ultrasonography in evaluating the endometrium of women with postmenopausal bleeding. Obstet Gynecol. 2018;131(5):e124-e129. Available from: https://pubmed.ncbi.nlm.nih.gov/29683910/

  19. Centers for Disease Control and Prevention. National Diabetes Statistics Report 2022. Atlanta, GA: CDC; 2022. Available from: https://www.cdc.gov/diabetes/data/statistics-report/index.html

  20. Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(11):3975-4011. Available from: https://pubmed.ncbi.nlm.nih.gov/26444994/

  21. U.S. Food and Drug Administration. Orange Book: approved drug products with therapeutic equivalence evaluations. Available from: https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm

  22. Prior JC. Progesterone for symptomatic perimenopause treatment: progesterone politics, physiology and potential for perimenopause. Facts Views Vis Obgyn. 2011;3(2):109-120. Available from: https://pubmed.ncbi.nlm.nih.gov/25009298/

  23. Caufriez A, Leproult R, L'Hermite-Baleriaux M, Copinschi G. Progesterone prevents sleep disturbances and modulates GH, TSH, and melatonin secretion in postmenopausal women. J Clin Endocrinol Metab. 2011;96(4):E614-E623. Available from: https://pubmed.ncbi.nlm.nih.gov/21289258/

  24. Pavlovic JM, Allshouse AA, Santoro NF, et al. Sex hormones in women with and without migraine: evidence of migraine-specific hormone profiles. Neurology. 2016;87(1):49-56. Available from: https://pubmed.ncbi.nlm.nih.gov/27251885/

  25. Pickar JH, Bon C, Amadio JM, Mirkin S, Bernick B. Pharmacokinetics of the first combination 17beta-estradiol/progesterone capsule in clinical development for menopausal hormone therapy. Menopause. 2015;22(12):1308-1316. Available from: https://pubmed.ncbi.nlm